-+ 0.00%
-+ 0.00%
-+ 0.00%

DAEHWA Pharm faces KOSDAQ disclosure-violator designation over contract termination reversal, late filing

PUBT·10/12/2026 09:31:43
Listen to the news
DAEHWA Pharm faces KOSDAQ disclosure-violator designation over contract termination reversal, late filing
  • DAEHWA Pharm flagged for potential designation as a disclosure-rule violator on Korea’s KOSDAQ market.
  • Case covers one disclosure reversal tied to termination of a single sales-supply contract.
  • Also cites one disclosure failure for delayed reporting of the contract termination; cause dated Oct. 10, 2023.
  • Exchange set Nov. 4, 2026 as the deadline to decide on formal violator status.
  • Notice warns trading could be halted for one day if penalty points reach 8.0 or more.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DAEHWA Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012900744), on October 12, 2026, and is solely responsible for the information contained therein.